Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effects of UCP2 -866 G/A and ADRB3 Trp64Arg on rosiglitazone response in Chinese patients with Type 2 diabetes.

British journal of clinical pharmacology - 1 Jul 2009

Yang Min, Huang Qiong, Wu Jing, Yin Ji-Ye, Sun Hong, Liu Hai-Ling, Zhou Hong-Hao, Liu Zhao-Qian

Abstract excerpt

AIMS: The aim of this study was to explore the impact of UCP2 and ADRB3 genetic polymorphisms on the therapeutic efficacy of rosiglitazone in Chinese Type 2 diabetes (T2DM) patients. METHODS: A total of 199 T2DM patients and 155 healthy volunteers were enrolled to identify UCP2 -866 G/A genotypes...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood Glucose
Share to Hypoglycemic Agents
Share to Ion Channels

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mitochondrial Proteins

Share to Receptors, Adrenergic, beta-3

Share to Rosiglitazone

Share to Thiazolidinediones

Share to Uncoupling Protein 2

Source

Open in PubMed Open full text

Identifiers

PMID: 19659999
DOI: 10.1111/j.1365-2125.2009.03431.x
PMCID: PMC2732936

Genes

ADRB3
UCP2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-19659999-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effects of UCP2 -866 G/A and ADRB3 Trp64Arg on rosiglitazone response in Chinese patients with Type 2 diabetes.PMID 19659999Read ↗

Impact of retinol binding protein 4 polymorphism on rosiglitazone response in Chinese type 2 diabetic patients.Semantic proximity Read ↗

Association of PAX4 genetic variants with oral antidiabetic drugs efficacy in Chinese type 2 diabetes patients.Semantic proximity Read ↗

Effect of genetic polymorphism of UCP2-866 G/A on repaglinide response in Chinese patients with type 2 diabetes.Semantic proximity Read ↗

Impact of genetic polymorphisms of leptin and TNF-α on rosiglitazone response in Chinese patients with type 2 diabetesSemantic proximity Read ↗

PPAR-γ2 and PTPRD gene polymorphisms influence type 2 diabetes patients' response to pioglitazone in China.Semantic proximity Read ↗

Effects of the peroxisome proliferator activated receptor-γ coactivator-1α (PGC-1α) Thr394Thr and Gly482Ser polymorphisms on rosiglitazone response in Chinese patients with type 2 diabetes mellitus.Semantic proximity Read ↗

Association of uncoupling protein-2 -866G/A and Ala55Val polymorphisms with susceptibility to type 2 diabetes mellitus: A meta-analysis of case-control studies.Semantic proximity Read ↗

Adiponectin gene polymorphism rs2241766 T/G is associated with response to pioglitazone treatment in type 2 diabetic patients from southern China.Semantic proximity Read ↗

Effects of ABCA1 variants on rosiglitazone monotherapy in newly diagnosed type 2 diabetes patients.Semantic proximity Read ↗

NeuroD1 A45T and PAX4 R121W polymorphisms are associated with plasma glucose level of repaglinide monotherapy in Chinese patients with type 2 diabetes.Semantic proximity Read ↗

Association of a SLC30A8 genetic variant with monotherapy of repaglinide and rosiglitazone effect in newly diagnosed type 2 diabetes patients in China.Semantic proximity Read ↗

Uncoupling protein 2 promoter polymorphism -866G/A affects its expression in beta-cells and modulates clinical profiles of Japanese type 2 diabetic patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.